Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motolimod with Cetuximab and Nivolumab in Head and Neck Cancer
NCT02124850Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of motolimod in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Change in immune biomarkers at 4 weeks. Started Oct 2014; status: terminated.
02
Drugs
motolimod
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02124850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02124850.